Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Academic Article uri icon

Overview

authors

  • Allan, John
  • Pinilla-Ibarz, Javier
  • Gladstone, Douglas E
  • Patel, Krish
  • Sharman, Jeff P
  • Wierda, William G
  • Choi, Michael Y
  • O'Brien, Susan M
  • Shadman, Mazyar
  • Davids, Matthew S
  • Pagel, John M
  • Yimer, Habte A
  • Ward, Renee
  • Acton, Gary
  • Taverna, Pietro
  • Combs, Daniel L
  • Fox, Judith A
  • Furman, Richard R
  • Brown, Jennifer R

publication date

  • April 1, 2022

Research

keywords

  • Neoplasms
  • Protein Kinase Inhibitors

Identity

PubMed Central ID

  • PMC8968902

Scopus Document Identifier

  • 85127883243

Digital Object Identifier (DOI)

  • 10.3324/haematol.2021.280061

PubMed ID

  • 34937320

Additional Document Info

volume

  • 107

issue

  • 4